Skip to main content
Log in

Antihypoxic and Antinecrotic Effect of Mexidol in Skin Ischemia

  • Pharmacology and Toxicology
  • Published:
Bulletin of Experimental Biology and Medicine Aims and scope

Abstract

Course treatment with mexidol in a dose of 25 mg/kg for 3 days decreased activities of aspartate transaminase and creatine phosphokinase in the plasma on day 3 after the incidence of skin ischemia (by 1.3 and 1.66 times, respectively). Under these conditions the index of cytolysis decreased by 1.3 times. Therefore, mexidol prevented progression of necrotic processes in the skin. Mexidol therapy of animals with skin ischemia restored the reserve capacity of systems for energy supply and antioxidant defense. The systems of NADH-ubiquinone reductase and succinate-ubiquinone reductase served as the targets for the action of mexidol. Mexidol significantly decreased the damaging effect of reactive oxygen species. Dermatoprotective properties of mexidol were associated with its influence on the energy supply system (regulation of enzyme activity in the electron transport chain, ubiquinone metabolism) and antioxidant defense.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

REFERENCES

  1. S. V. Vasil’eva, V. P. Galenko-Yaroshevskii, Yu. Yu. Fedchenko, et al., Byull. Eksp. Biol. Med., Suppl. 3, 97–101 (2002).

    Google Scholar 

  2. P. A. Galenko-Yaroshevskii, I. S. Chekman, and N. N. Gorchakova, Essays on Pharmacology of Preparations for Metabolic Therapy [in Russian], Moscow (2001).

  3. V. V. Gatsura, V. V. Pichugin, L. N. Sernov, and L. D. Smirnov, Kardiologiya, No. 11, 59–62 (1996).

  4. A. V. Zadorozhnyi, V. A. Popkov, V. P. Galenko-Yaroshevskii, et al., Byull. Eksp. Biol. Med., 138, No.9, 290–294 (2004).

    Google Scholar 

  5. L. D. Smirnov and K. M. Dyumaev, Directed Search for Physiologically Active Substances [in Russian], Riga (1987), pp. 5–44.

  6. L. O. Chernukhina, G. V. Donchenko, and V. M. Kovalenko, Ukr. Biokhim. Zh., No. 4, 514–518 (1974).

  7. N. Chen, Y. Liu, and L. Holtzman, J. Lab. Clin. Med., 136, No.1, 58–65 (2000).

    CAS  PubMed  Google Scholar 

  8. G. P. Littarru, D. Jones, J. Scholler, and K. Folkers, Int. J. Vit. Nutr. Res., 42, No.1, 127–128 (1972).

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

__________

Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 139, No. 2, pp. 170–174, February, 2005

Rights and permissions

Reprints and permissions

About this article

Cite this article

Galenko-Yaroshevskii, V.P., Bagmetova, E.N., Fil’chukova, I.A. et al. Antihypoxic and Antinecrotic Effect of Mexidol in Skin Ischemia. Bull Exp Biol Med 139, 202–206 (2005). https://doi.org/10.1007/s10517-005-0248-8

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10517-005-0248-8

Key Words

Navigation